摘要
2005年国际上4个不同的研究小组同时各自独立地检测到JAK2-V617F体细胞突变,该突变的出现意味着造血细胞对生长因子高度敏感及其增殖不再依赖于细胞因子。JAK2突变的发现,彻底改变了BCR-ABL阴性骨髓增殖性肿瘤(myeloproliferative neoplasm,MPN)的诊断策略,尤其是对真性红细胞增多症(polycythemia vera,PV)的诊断,此后又相继在PV中发现JAK2 exonl2突变。
To discuss the clinical feature and diagnosis of the JAK2 exon13 mutation in polycythemia combined monoclonal gammopathy of undetermined significance(MGUS).We analyzed the diagnosis of the JAK2 exon13 mutation in polycythemia combined MGUS,and reviewed related literature.According to clinical feature and related detection,the patient was diagnosed the JAK2 exon13 mutation in polycythemia combined MGUS.The JAK2 exon13 mutation in polycythemia combined MGUS is rare,the correlation of JAK2 exon13 mutation in polycythemia needs further research.
出处
《临床血液学杂志》
CAS
2015年第6期993-995,共3页
Journal of Clinical Hematology
基金
中央高校基金项目资助(No:31920140074)
宁夏自然科学基金项目资助(No:NZ14182)